28.46

0.18% 0.05

After Hours: 27.95 -0.51 -1.79%

Teva Pharmaceutical Industries Ltd Adr (TEVA)

Overview News Price History Option Chain Financials Why TEVA Down? Discussions Forecast Stock Split Dividend History

Teva Pharmaceutical Industries Ltd Adr stock is traded at $28.46, with a volume of 8.51M. It is up +0.18% in the last 24 hours and up +15.69% over the past month. Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Previous Close:

$28.41

Open:

$28.4

24h Volume:

8.51M

Relative Volume:

0.76

Market Cap:

$32.65B

Revenue:

$16.70B

Net Income/Loss:

$-157.13M

P/E Ratio:

-196.82

EPS:

-0.1446

Net Cash Flow:

$1.19B

1W Performance:

+5.84%

1M Performance:

+15.69%

6M Performance:

+64.99%

1Y Performance:

+59.71%

1-Day Range:

$28.00

$28.68

1-Week Range:

$26.46

$28.68

52-Week Range:

$12.46

$28.68

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile

Name

Teva Pharmaceutical Industries Ltd Adr

Sector

Healthcare (1133)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

972 (3) 914-8213

Address

TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV

Employee

35,686

Twitter

@TevaUSA

Next Earnings Date

2025-01-29

Latest SEC Filings

TEVA's Discussions on Twitter

Compare TEVA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TEVA Teva Pharmaceutical Industries Ltd Adr	28.46	32.59B	16.70B	-157.13M	1.19B	-0.1446
ZTS Zoetis Inc	118.65	53.06B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	14.18	45.11B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	9.52	42.44B	14.26B	1.98B	2.47B	0.4327
UTHR United Therapeutics Corp	489.31	20.84B	3.08B	1.24B	1.07B	25.61

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-05-25	Initiated	Scotiabank	Sector Outperform
Jun-06-25	Initiated	Goldman	Buy
May-28-25	Initiated	Truist	Buy
May-12-25	Upgrade	JP Morgan	Neutral → Overweight
Jul-10-24	Upgrade	Argus	Hold → Buy
Mar-08-24	Upgrade	JP Morgan	Underweight → Neutral
Feb-12-24	Upgrade	Piper Sandler	Neutral → Overweight
Jan-23-24	Upgrade	Jefferies	Hold → Buy
Jan-03-24	Upgrade	Piper Sandler	Underweight → Neutral
Dec-18-23	Initiated	HSBC Securities	Buy
Nov-27-23	Upgrade	UBS	Neutral → Buy
Jul-06-23	Upgrade	UBS	Sell → Neutral
May-25-23	Initiated	Morgan Stanley	Equal-Weight
May-18-23	Upgrade	Evercore ISI	In-line → Outperform
Jan-19-23	Downgrade	Jefferies	Buy → Hold
Nov-14-22	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	UBS	Neutral → Sell
Oct-21-22	Resumed	Jefferies	Buy
Aug-05-22	Upgrade	BofA Securities	Neutral → Buy
Jun-14-22	Resumed	UBS	Neutral
May-17-22	Upgrade	BofA Securities	Underperform → Neutral
May-04-22	Downgrade	Piper Sandler	Neutral → Underweight
Apr-05-22	Upgrade	Barclays	Equal Weight → Overweight
Mar-25-22	Upgrade	Bernstein	Mkt Perform → Outperform
Jan-27-22	Downgrade	Argus	Buy → Hold
Oct-28-21	Downgrade	Raymond James	Outperform → Mkt Perform
May-04-21	Downgrade	UBS	Buy → Neutral
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform
Nov-25-20	Initiated	Oppenheimer	Perform
Aug-06-20	Upgrade	Barclays	Underweight → Equal Weight
Jul-27-20	Resumed	Goldman	Neutral
Jun-01-20	Upgrade	SunTrust	Hold → Buy
Apr-24-20	Resumed	Citigroup	Neutral
Apr-06-20	Upgrade	UBS	Neutral → Buy
Feb-24-20	Downgrade	Edward Jones	Hold → Sell
Nov-12-19	Upgrade	JP Morgan	Underweight → Neutral
Oct-17-19	Upgrade	Gabelli & Co	Hold → Buy
Aug-07-19	Downgrade	Evercore ISI	Outperform → In-line
Jul-19-19	Initiated	Wolfe Research	Peer Perform
Jul-15-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jul-10-19	Resumed	Credit Suisse	Neutral
Jul-05-19	Upgrade	Argus	Hold → Buy
Jun-11-19	Initiated	Barclays	Underweight
Jun-03-19	Upgrade	Oppenheimer	Perform → Outperform
May-30-19	Downgrade	BofA/Merrill	Buy → Underperform
May-28-19	Downgrade	UBS	Buy → Neutral
Mar-20-19	Initiated	SunTrust	Hold
Mar-07-19	Resumed	UBS	Buy

View All

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Latest News

Nov 30, 2025

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - Finviz

Nov 30, 2025

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - The Motley Fool

Nov 30, 2025

Nov 28, 2025

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December - Sahm

Nov 28, 2025

Nov 27, 2025

Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd? - Sahm

Nov 27, 2025

Nov 26, 2025

Teva stock hits 52-week high at 26.38 USD - Investing.com

Nov 26, 2025

Nov 25, 2025

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - Sahm

Nov 25, 2025

Nov 19, 2025

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges - Sahm

Nov 19, 2025

Nov 17, 2025